학술논문
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
Document Type
Article
Author
Source
In The Lancet Infectious Diseases February 2012 12(2):111-118
Subject
Language
ISSN
1473-3099